Relationship of possible biomarkers with malignancy of thymic tumors: a meta-analysis
Authors:
Preprint
- 31 March 2020
- preprint
- Published by Springer Nature in Research Square
Abstract
Background : Role of biomarkers for promotion of tumor proliferation (BPTPs) and for promotion of apoptosis (BPAs) in thymic malignant tumors is still unclear. The purpose of this study was to evaluate the relationship between BPTPs and/or BPAs and malignancy of thymic malignant tumors. Methods : Studies on thymic malignant tumors and biomarkers were searched in PubMed, ISI Web of Knowledge, and Embase databases, and all statistical analyses were conducted using Review Manager. Results: Twelve articles related to biomarkers and thymic malignant tumors were selected and analyzed. A relationship between BPAs and Masaoka stage was demonstrated for four markers, namely Bax, p73, Casp-9 and Bcl-2, included 138 stage I/II patients and 74 stage III/IV patients, and BPAs were significantly correlated with high Masaoka staging (P = 0.03). We further found a relationship between BPAs and degree of malignancy for four markers, namely Bax, p73, Casp-9 and Bcl-2, included 176 thymoma patients and 36 thymic carcinoma patients, and BPAs were significantly correlated with thymic carcinoma (P = 0.010). In addition, a relationship between BPTP and Masaoka staging was demonstrated for seven markers, namely Podoplanin, Glut-1, Muc-1, Egfr, Igf1r, c-Jun, and n-Ras, included 373 patients with stage I/II and 212 patients with stage III/IV, and BPTPs were significantly correlated with high Masaoka staging (P < 0.001). We also found a relationship between BPTPs and degree of malignancy for ten markers, namely Mesothelin, c-Kit(CD117), Egfr, Lat-1, Muc-1,Ema, Glut-1, Igf1r, c-Jun, and n-Ras , included 748 thymoma patients and 280 thymic carcinoma patients, and BPTPs were significantly correlated with thymic carcinoma (P < 0.001). Conclusion: These findings show that high levels of BPTPs or BPAs are more closely related to thymic carcinoma and Masaoka stage III/IV, suggesting that BPTPs and BPAs may play an important role in the occurrence and development of thymic malignant tumors.Keywords
All Related Versions
- Published version: BMC Cancer, 20 (1), 1.
This publication has 39 references indexed in Scilit:
- Expression of c-Jun, p73, Casp9, and N-ras in thymic epithelial tumors: relationship with the current WHO classification systemsDiagnostic Pathology, 2012
- Molecular Analysis of ThymomaPLOS ONE, 2012
- MUC1 expression in thymic epithelial tumors: MUC1 may be useful marker as differential diagnosis between type B3 thymoma and thymic carcinomaVirchows Archiv, 2011
- Tumour eosinophilia combined with an immunohistochemistry panel is useful in the differentiation of type B3 thymoma from thymic carcinomaInternational Journal of Experimental Pathology, 2010
- L‐type amino acid transporter 1 (LAT1) is frequently expressed in thymic carcinomas but is absent in thymomasJournal of Surgical Oncology, 2009
- Mutational status of EGFR and KIT in thymoma and thymic carcinomaLung Cancer, 2008
- Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung CancerJNCI: Journal of the National Cancer Institute, 2005
- Tyrosine kinase receptor expression in thymomasJournal of Cancer Research and Clinical Oncology, 2004
- KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomasThe Journal of Pathology, 2004
- Proliferative Activity and Apoptosis in Thymic Epithelial NeoplasmsLaboratory Investigation, 2002